Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM ...

Lilly, a sweet and social 1-year-old old terrier with a lot of positive qualities, is available for adoption at The Cat House ...

Lilly Bells was stuck in a tree, 30 feet off the ground, for two whole days. Start the day smarter. Get all the news you need ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Bethany Lilly, a Leukemia & Lymphoma Society rep, asked a House panel to remember the sickest patients when considering ...

Detective Cordelia Cupp uncovers the truth through careful investigation and attention to detail, culminating in a shocking ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Sahara, Safari, Lek, Lilly and Naree are among the rescue dogs working at the site of the building that collapsed in Bangkok ...

UNICEF works to increase support and understanding of non-communicable diseases (NCDs) in childhood in low- and middle-income countries.

Amid a housing crisis, four cities are finding success in Utah’s moderate-income housing program to spur construction and ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...